Xin Lang Ji Jin·2026-03-03 05:36Group 1 - The core point of the news is that BeiGene's stock has experienced a decline of 10.47% over the past four days, with a current price of 237.87 CNY per share and a market capitalization of 366.48 billion CNY [1] - BeiGene was founded on October 28, 2010, and went public on December 15, 2021. The company focuses on the research, development, production, and commercialization of innovative drugs [1] - The main revenue composition of BeiGene is derived from drug sales, accounting for 99.10%, while collaboration revenue constitutes 0.90% [1] Group 2 - Red土 Innovation Fund has a significant holding in BeiGene, with 37,400 shares in its Red土 Innovation Healthcare Stock A fund, representing 3.79% of the fund's net value [2] - The fund has incurred a floating loss of approximately 48,530 CNY today and a total floating loss of 109,770 CNY during the four-day decline [2] - The Red土 Innovation Healthcare Stock A fund was established on October 20, 2020, with a current size of 234 million CNY and a year-to-date return of 5.66% [2]